Abstract
Using a selective Gαq/11 protein antibody capture guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding approach, it has been possible to perform a quantitative pharmacological examination of the functional activity of the M1 muscarinic acetylcholine receptor (mAChR) in membranes prepared from human postmortem cerebral cortex. Oxotremorine-M caused a ≥2-fold increase in [35S]GTPγS-Gαq/11 binding with a pEC50 of 6.06 ± 0.16 in Brodmann's areas 23 and 25 that was almost completely inhibited by preincubation of membranes with the M1 mAChR subtype-selective antagonist muscarinic toxin-7. In addition, the orthosteric and allosteric agonists, xanomeline [3(3-hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine] and AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chloride), increased [35S]-GTPγS-Gαq/11 binding, but with reduced intrinsic activities, inducing maximal responses that were 42 ± 1 and 44 ± 2% of the oxotremorine-M-induced response, respectively. These data indicate that the M1 receptor is the predominant mAChR subtype coupling to the Gαq/11 G protein in these brain regions and that it is possible to quantify the potency and intrinsic activity of full and partial M1 mAChR receptor agonists in postmortem human brain using a selective Gαq/11 protein antibody capture [35S]GTPγS binding assay.
Footnotes
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.108.137968.
-
ABBREVIATIONS: mAChR, muscarinic acetylcholine receptor; CNS, central nervous system; GTPγS, guanosine 5′-O-(3-thiotriphosphate); SPA, scintillation proximity assay; AC-42, 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chloride; xanomeline, 3(3-hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; MT-7, muscarinic toxin-7; NEM, N-ethylmaleimide.
- Received February 12, 2008.
- Accepted February 26, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|